120 related articles for article (PubMed ID: 37965902)
1. Investigation of
Ciftci N; Sargin I; Arslan G; Karakurt S; Arslan U
Nanomedicine (Lond); 2023 Oct; 18(24):1719-1731. PubMed ID: 37965902
[No Abstract] [Full Text] [Related]
2. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
Turk Dagi H; Kus H; Arslan U; Tuncer I
Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic susceptibilities of the Vibrionaceae to meropenem and other antimicrobial agents.
Clark RB
Diagn Microbiol Infect Dis; 1992 Jul; 15(5):453-5. PubMed ID: 1643823
[TBL] [Abstract][Full Text] [Related]
4. Study of
Zhang W; Guo Y; Yang Y; Dong D; Zheng Y; Zhu D; Hu F
Microb Drug Resist; 2020 Mar; 26(3):204-210. PubMed ID: 31553260
[No Abstract] [Full Text] [Related]
5. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544
[TBL] [Abstract][Full Text] [Related]
6. Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.
Biagi M; Shajee A; Vialichka A; Jurkovic M; Tan X; Wenzler E
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932381
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia.
García-Rodríguez JA; García Sánchez JE; Muñoz Bellido JL; García Sánchez E; García García MI
J Chemother; 1991 Jun; 3(3):143-6. PubMed ID: 1919651
[TBL] [Abstract][Full Text] [Related]
8. The postantibiotic effect of meropenem and imipenem on selected bacteria.
Nadler HL; Pitkin DH; Sheikh W
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():225-31. PubMed ID: 2509416
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.
Sader HS; Jones RN
Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):384-91. PubMed ID: 8354307
[TBL] [Abstract][Full Text] [Related]
10. Outer membrane permeability of Serratia marcescens to meropenem and imipenem.
Raimondi A; Pessina A; Cocuzza G
J Chemother; 1994 Dec; 6(6):363-7. PubMed ID: 7699421
[TBL] [Abstract][Full Text] [Related]
11. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021.
Lee YL; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2023 Aug; 62(2):106867. PubMed ID: 37244423
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest.
Brown-Elliott BA; Killingley J; Vasireddy S; Bridge L; Wallace RJ
J Clin Microbiol; 2016 Jun; 54(6):1586-1592. PubMed ID: 27053677
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
Bedenic B; Goic-Barisic I; Budimir A; Tonkic M; Mihajkevic LJ; Novak A; Sviben M; Plecko V; Punda-Polic V; Kalenic S
J Chemother; 2010 Jun; 22(3):147-52. PubMed ID: 20566417
[TBL] [Abstract][Full Text] [Related]
16. Activity of meropenem and other antimicrobial agents against uncommon gram-negative organisms.
Clark RB; Joyce SE
J Antimicrob Chemother; 1993 Aug; 32(2):233-7. PubMed ID: 8226425
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial and antibiofilm efficacy of colistin & meropenem conjugated silver nanoparticles against Escherichia coli and Klebsiella pneumoniae.
Şirin MC; Cezaroğlu Y; Sesli Çetin E; Arıdoğan B; Trak D; Arslan Y
J Basic Microbiol; 2023 Dec; 63(12):1397-1411. PubMed ID: 37821405
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q
BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
Chang CY; Lee YL; Huang YT; Ko WC; Ho MW; Hsueh PR
Int J Antimicrob Agents; 2023 Jun; 61(6):106815. PubMed ID: 37059343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
